Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.262
Index Copernicus (ICV) – 155.19, MNiSW – 15
Rejection rate – 65.13%
License – Creative Commons: Attribution 3.0 Unported (CC BY 3.0)
ISSN 1899–5276 (print),   ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 3, March, p. 305–311

doi: 10.17219/acem/66207

PubMed ID: 29558042

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Deregulated expression of HDAC3 in colorectal cancer and its clinical significance

Masoumeh Nemati1,A,C,D,F, Naser Ajami2,C,D,E,F, Mehrdad Asghari Estiar3,C,E,F, Saleheh Rezapour4,B,F, Reyhaneh Ravanbakhsh Gavgani1,B,F, Shahryar Hashemzadeh5,6,B,F, Hossein Samadi Kafil7,A,E,F, Ebrahim Sakhinia4,A,C,E,F

1 Department of Biology, Faculty of Natural Sciences, Tabriz University, Iran

2 Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Iran

3 Department of Medical Genetics, Tehran University of Medical Sciences, Iran

4 Division of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Iran

5 Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Iran

6 Department of General and Thoracic Surgery, Tabriz University of Medical Sciences, Iran

7 Drug Applied Research Center, Tabriz University of Medical Sciences, Iran

Abstract

Background. To date, 4 classes of histone deacetylases (HDACs) have been identified in humans. Class I HDACs are zinc-dependent and NAD+-independent enzymes, and include 4 isoforms closely related to yeast RPD3: HDAC1, 2, 3, and 8.
Objectives. The aims of the study were to quantitatively evaluate the expression of HDAC3 in colorectal cancer (CRC) and to correlate its expression levels with clinicopathological parameters.
Material and Methods. We characterized expression patterns of HDAC3 as class I HDAC isoforms in a cohort of 48 CRC patients by quantitative (real-time) reverse transcription polymerase chain reaction (RT-PCR). In addition, the potential relationship between HDAC3 expression levels and clinicopathological parameters in patients suffering from CRC was explored.
Results. We found that HDAC3 was highly expressed in colorectal tumors compared to normal colorectal tissues (p < 0.05). Furthermore, we found significant correlations between HDAC3 expression levels and tumor differentiation grades (p < 0.05).
Conclusion. In this prospective study we identified a pronounced HDAC3 expression pattern in CRC. Our findings support an important role of HDAC3 as a complementary molecular marker for existing histopathological diagnostic elements; it might also have applications in prognostic and targeted therapy. Furthermore, HDAC3 can be used as a biomarker to differentiate between tumor borders and margins, and it may also be useful for characterizing field cancerization in CRC.

Key words

HDAC3, deregulation, prognosis, colorectal cancer

References (50)

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64(1):9–29.
  2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.
  3. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA: Cancer J Clin. 2009;59(6):366–378.
  4. Hasanpour M, Galehdari H, Masjedizadeh A, Ajami N. A unique profile of adenomatous polyposis coli gene mutations in Iranian patients suffering sporadic colorectal cancer. Cell J. 2014;16(1):17–24.
  5. Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R. Epidemiology and molecular genetics of colorectal cancer in iran: A review. Arch Iran Med. 2009;12(2):161–169.
  6. Magalhaes B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: Systematic review and meta-analysis. Eur J Cancer Prev. 2012;21(1):15–23.
  7. Soreide K, Nedrebo BS, Knapp JC, Glomsaker TB, Soreide JA, Korner H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist. Surg Oncology. 2009;18(1):31–50.
  8. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–2460.
  9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–767.
  10. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19–25.
  11. Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011;2011: 792362. doi: 10.1155/2011/792362
  12. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286–298.
  13. Schweiger MR, Hussong M, Rohr C, Lehrach H. Genomics and epigenomics of colorectal cancer. Wiley Interdiscip Rev Syst Biol Med. 2013;5(2):205–219.
  14. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26(37):5420–5432.
  15. Sun WJ, Zhou X, Zheng JH, et al. Histone acetyltransferases and deacetylases: Molecular and clinical implications to gastrointestinal carcinogenesis. Acta Biochim Biophys Sin. 2012;44(1):80–91.
  16. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38–51.
  17. Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene. 2001;20(24):3110–3115.
  18. Fang JY. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers. J Gastroenterol Hepatol. 2005;20(7):988–994.
  19. Watson PJ, Fairall L, Santos GM, Schwabe JW. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature. 2012; 481(7381):335–340.
  20. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9(3): 206–218.
  21. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012;4(1):5.
  22. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer. 2004;4(10):769–780.
  23. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: From improved survival to potential cure. Oncology. 2010;78(3–4):237–248.
  24. Coppede F, Lopomo A, Spisni R, Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol. 2014;20(4):943–956.
  25. Langan RC, Mullinax JE, Raiji MT, et al. Colorectal cancer biomarkers and the potential role of cancer stem cells. J Cancer. 2013;4(3):241–250.
  26. Jiang Y, Hsieh J. HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels. Proc Natl Acad Sci U S A. 2014;111(37):13541–1356.
  27. Telles E, Seto E. Modulation of cell cycle regulators by HDACs. Front Biosci (Schol Ed). 2012;4:831–839.
  28. Hayashi A, Horiuchi A, Kikuchi N, et al. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer. 2010;127(6):1332–1346.
  29. Muller BM, Jana L, Kasajima A, et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer – overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC cancer. 2013;13:215.
  30. Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98(3):604–610.
  31. Wu LM, Yang Z, Zhou L, et al. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One. 2010;5(12): e14460.
  32. Liby P, Kostrouchova M, Pohludka M, et al. Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours. Folia Biol. 2006;52(1–2):21–33.
  33. Lehmann A, Denkert C, Budczies J, et al. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC cancer. 2009;9:395.
  34. Adams H, Fritzsche FR, Dirnhofer S, Kristiansen G, Tzankov A. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin’s lymphoma. Expert Opin Ther Targets. 2010;14(6):577–584.
  35. Moreno DA, Scrideli CA, Cortez MA, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol. 2010;150(6):665–673.
  36. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281(19):13548–13558.
  37. Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14(6):1669–1677.
  38. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog. 2008;47(2):137–147.
  39. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19(10):1751–1759.
  40. Singh BN, Zhou H, Li J, et al. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol. 2011;7(12):1415–1428.
  41. Giudice FS, Pinto DS Jr, Nor JE, Squarize CH, Castilho RM. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One. 2013;8(3):e58672.
  42. Katoch O, Dwarakanath BS, Agrawala PK. HDAC inhibitors: Applications in oncology and beyond. HOAJ Biology. 2013;2(1):2.
  43. Carson R, Celtikci B, Fenning C, et al. HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL. Clin Cancer Res. 2015;21(14):3230–3240. doi: 10.1158/1078-0432.CCR-14-2701
  44. Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: From molecular mechanisms to clinical implications. Int J Biol Sci. 2014;10(7):757–770.
  45. Kim HJ, Bae SC. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3(2):166–179.
  46. Bhaskara S, Knutson SK, Jiang G, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 2010;18(5):436–447.
  47. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: The nuclear and epigenetic components. Handb Exp Pharmacol. 2011;206:13–37.
  48. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol. 2009;35(3):537–546.
  49. Hashemzadeh S, Arabzadeh AA, Estiar MA, et al. Clinical utility of measuring expression levels of Stanniocalcin 2 in patients with colorectal cancer. Med Oncol. 2014;31(10):237.
  50. Stypula-Cyrus Y, Damania D, Kunte DP, et al. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One. 2013;8(5): e64600.